Dave Murdoch
Director of Corporate Communications
774.405.5719
david.murdoch@us.sumitomo-pharma.com
Thomas Hill
VP, Head of Corporate Communications
and Employee Engagement
949.239.3598
thomas.hill@us.sumitomo-pharma.com
News Releases
Stay up to date with SMPA
The latest company news, press releases, and resources about Sumitomo Pharma America, our employees, our partners, and our latest innovations.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 23, 2023
– ORGOVYX is the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Approved for Advanced Prostate Cancer in Canada – MISSISSAUGA, Ontario, Oct. 23, 2023...
-
Oct 19, 2023
Sumitomo Pharma Canada, Inc. and Pfizer Canada today announced that Health Canada has granted a Notice of Compliance (NOC) for MYFEMBREE (Relugolix, estradiol and norethindrone acetate tablets)...
-
Oct 2, 2023
CAMBRIDGE, Mass., October 2, 2023 – Sumitomo Pharma America, Inc. (SMPA) today announced Ron Gimbel has been appointed as the Company’s new Chief Financial Officer. Mr. Gimbel, an industry...
-
Sep 15, 2023
Gedeon Richter Plc. ('Richter') together with Sumitomo Pharma America, Inc. ('SMPA') and Sumitomo Pharma Switzerland GmbH ('SMPS') today announce that the Committee for Medicinal Products for...
-
Sep 11, 2023
–Vibegron Met Both Co-Primary Endpoints Demonstrating Statistically Significant Reductions in Daily Micturition and Urgency Episodes, Compared to Placebo at Week 12– –Vibegron Met All...